Search results
Results from the WOW.Com Content Network
Disruptive mood dysregulation disorder (DMDD) is a mental disorder in children and adolescents characterized by a persistently irritable or angry mood and frequent temper outbursts that are disproportionate to the situation and significantly more severe than the typical reaction of same-aged peers.
Casimersen was approved for medical use in the United States in February 2021, [1] [2] [6] and it is the first FDA-approved targeted treatment for people who have a confirmed mutation of the DMD gene that is amenable to skipping exon 45. [2]
This is a list of investigational social anxiety disorder drugs, or drugs that are currently under development for clinical use in the treatment of social anxiety disorder (SAD; or social phobia) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.
Ecopipam (development codes SCH-39166, EBS-101, and PSYRX-101) is a dopamine antagonist which is under development for the treatment of Lesch–Nyhan syndrome, Tourette syndrome, speech disorders, and restless legs syndrome. [2] It is taken by mouth. [3] Ecopipam acts as a selective dopamine D 1 and D 5 receptor antagonist. [2]
It is available as a generic medication. [10] In 2022, it was the 275th most commonly prescribed medication in the United States, with more than 800,000 prescriptions. [13] [14] Guanfacine is approved by the US FDA for monotherapy treatment of ADHD, [3] as well as being used for augmentation of stimulant medications.
The approval of Zepbound follows a series of other weight loss drugs approved to treat medical conditions other than obesity and diabetes. In March, the weight loss drug Wegovy was FDA-approved to ...
In addition to post-treatment relapse, depressive symptoms can even recur in the course of long-term therapy (tachyphylaxis). Also, currently available antidepressants all elicit undesirable side-effects, and new agents should be divested of the distressing side-effects of both first and second-generation antidepressants.